{
  "docId": "019de075-814d-76ed-b6e6-6e437a6b6631",
  "docSlug": "56480dbdf83cce5ae4f2fad948f0ee58",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 26 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 26,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide highlights clinical trial outcomes and regulatory next steps.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-814d-76ed-b6e6-6e437a6b6631/11",
  "deckHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631",
  "deckJsonHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631.json",
  "deckAnchorHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.72,
        "x": 0.14,
        "y": 0.81
      },
      "kind": "callout",
      "text": "Preparing to Request End-of-Phase 2 Meeting with FDA",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d49fae4-9ce6-4fb6-a281-369eca29a5c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.94,
        "x": 0.03,
        "y": 0.31
      },
      "kind": "list",
      "text": "Sildenafil Cream-treated group showed meaningful improvement in the co-primary endpoint assessment that evaluated change from baseline in the Arousal-Sensation Domain of the Sexual Function Questionnaire, although the endpoint did not achieve statistical significance.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d568c445-8be3-4a53-9294-0fbbae43645c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.94,
        "x": 0.03,
        "y": 0.45
      },
      "kind": "list",
      "text": "Sildenafil Cream-treated group also showed improvements in the secondary endpoint and pre-specified exploratory endpoints that evaluated various aspects of the sexual experience: Sexual satisfaction, Arousal lubrication, Achievement and pleasure of orgasm, Sexual desire",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe6a2d5a-d928-4cd3-9b22-288fd77b34f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.94,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "Positive findings from the exploratory Phase 2b RESPOND study of Sildenafil Cream, 3.6% in women with Female Sexual Arousal Disorder support continued development of Sildenafil Cream and selection of proposed primary endpoint assessments for a Phase 3 study",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6fbd800-84ef-4a98-84ec-5e1fe79fcfde",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.45,
        "x": 0.03,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "1. The study did not demonstrate statisitcal significance for the co-primary or seconday efficacy enpoints.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5430c7ab-c092-4b7f-9404-9c3f1299e338",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.86,
        "x": 0.07,
        "y": 0.04
      },
      "kind": "title",
      "text": "Sildenafil Cream, 3.6% - Phase 2b RESPOND Study – Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34927605-8ef1-48de-a513-7109867e422b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 11,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "83faa245-7d21-49f3-aa4d-68f21da0e116",
      "evidence": "The deck presents the consequences of not addressing FSAD/FSIAD on pages 8-11",
      "position": 0,
      "objective": "Highlight the need for a treatment for FSAD/FSIAD",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}